Commercial

Noventure and Laboratorios Salvat enter into agreement to commercialise innovative medical device in Spain and Portugal for rhinitis and rhinosinusitis

February 21, 2018

The agreement will see the global launch of Noventure’s novel nasal mucoprotection product  Barcelona, Spain, February 21, 2018 – Noventure and Laboratorios Salvat, S.A. (Salvat), announce today that they have entered into an agreement in which Salvat will distribute Noventure’s nasal mucoprotection product in Spain and Portugal. The product contains a mucomimetic agent that forms […]

Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®

February 21, 2018

Amneal Pharmaceuticals has launched memantine hydrochloride extended-release capsules, the company’s AB-rated equivalent for Namenda XR®, in 7 mg, 14 mg, 21 mg and 28 mg strengths. The product is manufactured here in the United States in the company’s recently expanded Brookhaven, New York facility. Annual U.S. sales of Namenda XR® were $929 million, according to […]

Ashfield launches new commercial model to improve ROI

February 21, 2018

Ashfield, part of UDG Healthcare, a global leader in providing outsourced healthcare services, has announced the launch of a pioneering new commercial model called The Ashfield Solution. In response to global market trends, The Ashfield Solution is an agile, multi-channel engagement model underpinned by a field analytics engine. The proprietary solution addresses the challenges of […]

Envigo appoints Lynn Lewis as Senior Vice President of Global Sales

February 21, 2018

East Millstone, NJ, February 21, 2018 – Envigo, a leading provider of nonclinical contract research services and research models, today announced the appointment of Lynn Lewis to the position of Senior Vice President, Global Sales. She brings extensive knowledge in both science and business to the company through her successful career in pharmaceuticals and leadership roles […]

Phoenix Marketing Solutions Transforms to Phoenix Group

February 20, 2018

NEW PROVIDENCE, NJ (February 15, 2018) — Phoenix Marketing Solutions, a recognized leader in full-service medical communications and speakers bureau management, has announced its rebrand and will officially be known as Phoenix Group. The new company name aligns strategically with Phoenix Group’s core and vision — a multidisciplinary group unified with one common purpose: to transform […]

FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ER™ (amantadine) extended-release tablets for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions in Adults

February 20, 2018

BRIDGEWATER, N.J., Feb. 19, 2018 (GLOBE NEWSWIRE) — Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous system (CNS) treatments utilizing its proprietary osmotic drug delivery platform, announced today that the U.S. Food and Drug Administration (FDA) has approved OSMOLEX ER™, an amantadine extended release tablet, for […]

Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca

February 20, 2018

CARLSBAD, Calif., Feb. 20, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed IONIS-AZ5-2.5Rx (AZD2373) to the global, science-led biopharmaceutical company AstraZeneca (NYSE: AZN). IONIS-AZ5-2.5Rx is a Generation 2.5 antisense drug, discovered by Ionis and designed to inhibit an undisclosed target to treat a genetically associated form of kidney disease. […]

Amunix announces XTEN® and ProTIA technology licensing agreement with Celgene

February 20, 2018

MOUNTAIN VIEW, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) — Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapeutics, is pleased to announce that it has entered into a licensing agreement with Celgene. The agreement allows for the utilization of Amunix’s proprietary XTEN and ProTIA technology to augment […]

Global Anti-Depressant Drugs Market Expected to Reach $15,983 Million by 2023 – Allied Market Research

February 19, 2018

PORTLAND, Oregon and PUNE, India, February 16, 2018 /PRNewswire/ —   According to a new report published by Allied Market Research, titled, “Anti-depressant Drugs Market by Depression Disorder, Product, and Geography: Global Opportunity Analysis and Industry Forecast, 2017-2023,” the anti-depressant drugs market accounted for $13,755 million in 2016, and is estimated to reach $15,983 million […]

Global Gene Therapy Market Expected to Reach $4,402 Million by 2023 – Allied Market Research

February 19, 2018

PORTLAND, Oregon and PUNE, India, February 16, 2018 /PRNewswire/ —   According to a new report published by Allied Market Research, titled, “Gene Therapy Market by Vector Type, Gene Type, Application, and Geography: Global Opportunity Analysis and Industry Forecast, 2017-2023,” the global gene therapy market accounted for $584 million in 2016, and is estimated to […]

Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals

February 19, 2018

MORRISTOWN, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) — Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced the launch of an authorized generic version of Treximet® (sumatriptan/naproxen sodium) in the U.S. by the Company’s subsidiary, Macoven Pharmaceuticals, LLC. Treximet is a prescription medicine that contains sumatriptan and naproxen sodium (a NSAID) and is […]

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

February 19, 2018

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III […]

Rheumatoid Arthritis Drugs Market Worth $30.4 Billion by 2025: Grand View Research, Inc.

February 19, 2018

SAN FRANCISCO, February 19, 2018 /PRNewswire/ —   The global rheumatoid arthritis therapeutics market size is expected to reach USD 30.4 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of […]

FEEDBACK